Our results suggest that despite successful treatment with topical therapy, methotrexate, adalimumab, secukinumab, or guselkumab, young patients with psoriasis still exhibit a residual systemic inflammatory imprint, characterized by elevated disease-specific inflammatory markers (IFN-γ, TNF, IL-1β, IL-12p70, IL-17, but not IL-23) compared to controls, whereas they do not differ for non-specific inflammatory markers. Here, IL1B is linked to psoriasis.